West Pharmaceutical Services Inc - Asset Resilience Ratio
West Pharmaceutical Services Inc (WST) has an Asset Resilience Ratio of 18.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See West Pharmaceutical Services Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how West Pharmaceutical Services Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see West Pharmaceutical Services Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down West Pharmaceutical Services Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of West Pharmaceutical Services Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $791.30 Million | 18.53% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $791.30 Million | 18.53% |
Asset Resilience Insights
- Good Liquidity Position: West Pharmaceutical Services Inc maintains a healthy 18.53% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
West Pharmaceutical Services Inc Industry Peers by Asset Resilience Ratio
Compare West Pharmaceutical Services Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.29% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 22.60% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
ZEN Graphene Solutions Ltd
V:ZEN |
Medical Instruments & Supplies | 4.79% |
Annual Asset Resilience Ratio for West Pharmaceutical Services Inc (2007–2025)
The table below shows the annual Asset Resilience Ratio data for West Pharmaceutical Services Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.53% | $791.30 Million | $4.27 Billion | +5.23pp |
| 2024-12-31 | 13.30% | $484.60 Million | $3.64 Billion | -9.00pp |
| 2023-12-31 | 22.30% | $853.90 Million | $3.83 Billion | -2.43pp |
| 2022-12-31 | 24.73% | $894.30 Million | $3.62 Billion | +1.71pp |
| 2021-12-31 | 23.01% | $762.60 Million | $3.31 Billion | -6.68pp |
| 2020-12-31 | 29.69% | $829.50 Million | $2.79 Billion | +10.94pp |
| 2019-12-31 | 18.75% | $439.10 Million | $2.34 Billion | -2.43pp |
| 2018-12-31 | 21.19% | $337.40 Million | $1.59 Billion | +8.52pp |
| 2017-12-31 | 12.66% | $235.90 Million | $1.86 Billion | +0.84pp |
| 2016-12-31 | 11.83% | $203.00 Million | $1.72 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $1.70 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $1.67 Billion | -- |
| 2013-12-31 | 0.45% | $7.50 Million | $1.67 Billion | -0.34pp |
| 2012-12-31 | 0.79% | $12.40 Million | $1.56 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $1.29 Billion | -- |
| 2008-12-31 | 0.37% | $4.30 Million | $1.17 Billion | -1.40pp |
| 2007-12-31 | 1.77% | $21.00 Million | $1.19 Billion | -- |
About West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; sy… Read more